Iovance Biotherapeutics Inc. (IOVA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Iovance Biotherapeutics Inc. (IOVA) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How IOVA Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $263.5M | 34.3% | -153.1% | -$391.0M | -$336.2M | -45% |
| FY 2024 | $164.1M | 43.2% | -240.9% | -$372.2M | -$364.0M | -45% |
| FY 2023 | $1.2M | 44% | -38735% | -$444.0M | -$361.9M | -25.3% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring IOVA)
- ✓Live walkthrough of IOVA's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
IOVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +60.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IOVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IOVA. Explore sector supply chains on /butterfly.
IOVA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Iovance Biotherapeutics Inc. (IOVA)?
In FY 2025 (10-K), IOVA converted $263.5M of revenue into a 34.3% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).